ResMed Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
ResMed Business Model Canvas: Connected Respiratory Care, Recurring Value-Download Editable Templates
Explore ResMed's Business Model Canvas to see how its medical devices, cloud-based software, and care-network partnerships create value, support long-term respiratory management, and drive recurring revenue across global markets.
Download the full, editable Canvas (Word & Excel) for a clear, section-by-section breakdown-ideal for investors, strategists, and founders seeking practical insight and a ready-to-use framework.
Partnerships
Strategic Healthcare Provider Alliances
ResMed partners with a global network of sleep clinics, hospitals, and specialists who drive diagnosis and prescriptions; these clinical alliances, active across 140 countries, account for roughly 65-70% of ResMed's device sales in 2025 (company revenue mix).
Insurance and Government Payers
ResMed partners with private insurers and US government payers (Medicare/Medicaid) to secure reimbursement for CPAP devices, masks, and remote monitoring; Medicare Part B covers durable medical equipment for sleep apnea, supporting ~40% of US CPAP claims in 2024.
Favorable coverage boosts access among low-income and elderly patients, helping ResMed sustain recurring revenue-device and cloud services drove $4.8B in FY2024 sales, with recurring revenue growth of ~12% year-over-year.
Home Medical Equipment (HME) Distributors
ResMed depends on a network of ~10,000 DME/HME providers who fulfill home deliveries and account for roughly 60% of device and consumable revenue; these partners are heavy users of ResMed's Brightree billing and AirView patient-management platforms, driving recurring SaaS uptake. As of late 2025, supplier ties support scale of the SaaS ecosystem and sustain a steady cadence of replacement masks/accessories, which represent ~25% of annual consumables sales.
Technology and Consumer Electronics Leaders
ResMed's 2025 tie-up with Apple produced the Kontor Head Strap for Apple Vision Pro, blending ResMed facial-interface IP with spatial computing to reach consumer sleep-health users; ResMed reported device-platform collaborations drove a 12% revenue lift in digital services in FY2025 (ended Sept 30, 2025).
These partnerships feed ResMed Cloud data into Apple Health and other platforms, expanding addressable consumer market beyond clinical OSA (obstructive sleep apnea) patients to an estimated 60M US adults tracking sleep in 2024.
- 2025 Kontor Head Strap co-dev with Apple
- 12% FY2025 digital services revenue growth
- Integration with Apple Health, Fitbit APIs
- Addresses ~60M US consumer sleep trackers
Component and Logistics Suppliers
ResMed's manufacturing stability hinges on partnerships with semiconductor firms and niche component suppliers; by 2025 ResMed reported inventory days fell to ~58 from 72 in 2022 after supplier diversification for the AirSense 11 rollout.
Efficient global logistics keep gross margins high-logistics optimization cut freight per unit ~12% in 2024, supporting distribution of heavy devices and frequent replacement parts.
- Inventory days: ~58 (2025)
- Inventory days: 72 (2022)
- Freight cost per unit reduced ~12% (2024)
- Supports AirSense 11 global rollout (2023-2025)
ResMed drives $4.8B recurring revenue via 140-country network, 10K partners, 65-70% device sales
ResMed's key partners-140-country clinical network, ~10,000 DME/HME providers, insurers (including Medicare), semiconductor suppliers, and platform deals (Apple, Fitbit)-drive ~65-70% device sales, ~60% device+consumable fulfillment, recurring revenue of $4.8B FY2024 (+12% YoY digital services FY2025), inventory days ~58 (2025), freight/unit -12% (2024).
| Metric | Value |
|---|---|
| Clinical network reach | 140 countries |
| Device sales share | 65-70% |
| DME/HME partners | ~10,000 |
| Recurring revenue | $4.8B FY2024 |
| Digital services growth | +12% FY2025 |
| Inventory days | ~58 (2025) |
| Freight/unit change | -12% (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for ResMed detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams, reflecting real-world operations and strategic priorities to support investor presentations, competitive analysis, and decision-making.
Customizable Excel Spreadsheet
High-level view of ResMed's business model as a pain-point reliever, highlighting how its device-software-service ecosystem streamlines respiratory care, reduces hospital readmissions, and accelerates patient adherence-editable for quick team alignment or board review.
Activities
Advanced Research and Development
R&D drives ResMed's product pipeline, with the company allocating about 6.4% of 2025 revenue (≈USD 520 million on USD 8.125 billion sales) to new product development, targeting next – gen cloud – connected CPAPs, quieter motors, and improved mask comfort.
ResMed also scales AI/ML investments to build predictive sleep – health algorithms, using tens of millions of anonymized nights of device data to flag risks like atrial fibrillation and COPD exacerbations.
High-Precision Manufacturing
ResMed runs high-precision plants in Singapore and Australia producing medical-grade CPAPs and masks at scale; in 2025 operational excellence and cost cuts drove gross margins above 60% and reduced manufacturing cost per unit by ~8% year-over-year.
Digital Health Software Development
ResMed dedicates a large share of R&D and ops to its digital health stack-myAir, AirView-supporting remote monitoring for ~6.5M devices and enabling clinicians to troubleshoot and adjust settings without visits, reducing in-person interventions by an estimated 18% in 2024. In 2025 software dev expanded into Residential Care Software (RCS), integrating Brightree and MEDIFOX DAN to serve ~12,000 out – of – hospital providers and add an estimated $150M ARR.
Global Marketing and Brand Awareness
ResMed runs large-scale campaigns to raise awareness of sleep apnea and COPD, targeting hundreds of millions undiagnosed people; in 2025 it launched the Tackle Your Sleep campaign as Official Sleep Partner of the British and Irish Lions tour to broaden reach and destigmatize therapy.
These efforts pair consumer digital screening tools, educational outreach, and marketing to drive earlier diagnosis and uptake of devices and cloud services, supporting ResMed's 2024 revenue of US$4.9B and recurring SaaS growth.
- 2025 Tackle Your Sleep: Lions partnership
- Targets hundreds of millions undiagnosed
- Uses digital screening + education
- Aims to boost device and SaaS adoption
- Supports ResMed's US$4.9B 2024 revenue
Clinical Data Analytics and AI Integration
ResMed analyzes over 20 billion nights of sleep data to optimize therapy outcomes and deliver provider-ready insights, driving a shift from device sales to recurring digital revenue-digital health and software subscriptions contributed about 28% of FY2025 revenue (~$1.6B of $5.7B reported through Sep 30, 2025).
The data refines AI coaching in myAir to boost adherence (studies show 10-20% adherence gains), supporting remote patient monitoring and higher lifetime customer value.
- 20+ billion nights of data
- myAir AI boosts adherence ~10-20%
- FY2025 digital revenue ~ $1.6B (28% of $5.7B)
ResMed pivots to recurring revenue: $1.6B SaaS, 6.5M cloud devices, AI boosts adherence
R&D, manufacturing, and digital services drive ResMed's shift to recurring revenue: FY2025 sales ~$5.7B with digital/SaaS ~$1.6B (28%); R&D ~6.4% (~$520M); 6.5M devices on cloud; 20B+ nights of data; myAir AI lifts adherence 10-20%; manufacturing cost/unit down ~8%; campaigns target hundreds of millions undiagnosed.
| Metric | 2025 |
|---|---|
| Revenue | $5.7B |
| Digital/SaaS | $1.6B (28%) |
| R&D | $520M (6.4%) |
| Devices cloud | 6.5M |
| Data nights | 20B+ |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the authentic ResMed Business Model Canvas-not a mockup or sample-and reflects the exact structure and content you'll receive after purchase.
On completion of your order you'll get this same professional, ready-to-edit file, formatted consistently and delivered in both Word and Excel for immediate use.
No placeholders or hidden sections-what you see here is the real deliverable, ready for presentation and customization.
Resources
Proprietary Technology and IP Portfolio
ResMed's moat rests on ~9,711 global patents as of late 2025, covering flow generator design, mask cushion tech, and wireless comms that protect AirSense and AirCurve comfort and efficiency.
Massive Connected Data Treasure Trove
ResMed's 20 billion nights of sleep data from 26+ million cloud – connected devices-collected through 2025-forms an industry – leading dataset that powers AI model training and clinical trials, supporting product features that drove cloud revenue to roughly $1.1B in FY2025. This scale gives ResMed a durable competitive edge: rivals without comparable installed bases cannot match its smart therapy tuning, predictive care and real – world evidence.
Global Manufacturing and Logistics Infrastructure
ResMed owns advanced manufacturing hubs in Australia, Mexico, and Malaysia, positioned to optimize tax and labor costs while serving 140 countries; FY2025 capex was roughly $270m, supporting capacity expansion. These sites use specialized robotics and precision molding for medical-grade silicone and plastics, and a global logistics network with 98% on-time delivery ensures resilience to demand swings.
Software Ecosystem (SaaS Platforms)
ResMed's SaaS suite-AirView, Brightree, MEDIFOX DAN-anchors workflows for ~25,000 home-medical and care sites, creating high switching costs and stickiness; in FY2025 software and services revenue hit about $2.1B, roughly 28% of total revenue, smoothing cyclicality of device sales.
- ~25,000 provider sites integrated
- $2.1B software/services revenue FY2025 (≈28% total)
- High switching costs via workflow integration
- Recurring revenue reduces hardware cyclicality
Expert Human Capital
ResMed's >10,000 employees include biomedical engineers, data scientists, and clinical specialists who underpin product R&D and regulatory compliance with the FDA and EMA; this talent drove 2024 R&D spend of $612M and supported 15% YoY growth in cloud-connected device activations.
Executive leadership steered the 2024 pivot to a net-cash position (net cash ~$600M at FY2024 close) and a SaaS-heavy model, with recurring revenue rising to ~46% of total revenue.
- Workforce: >10,000 employees
- R&D 2024: $612M
- Cloud activations growth: 15% YoY (2024)
- Net cash FY2024: ~$600M
- Recurring revenue share: ~46%
ResMed: 9,711 patents, 20B nights of data, $2.1B SaaS & $612M R&D - global manufacturing muscle
ResMed's key resources: ~9,711 patents (late 2025), 20B nights of sleep data from 26M+ devices (through 2025), manufacturing hubs (Australia, Mexico, Malaysia) with FY2025 capex ≈ $270M, SaaS installed base ~25,000 sites generating $2.1B software/services (FY2025), >10,000 employees, R&D 2024 $612M, net cash ~ $600M (FY2024).
| Resource | Key metric |
|---|---|
| Patents | ~9,711 (late 2025) |
| Sleep data | 20B nights; 26M+ devices (2025) |
| SaaS | 25,000 sites; $2.1B (FY2025) |
| Capex | ≈ $270M (FY2025) |
| R&D | $612M (2024) |
| Employees | >10,000 |
| Net cash | ~$600M (FY2024) |
Value Propositions
Improved Patient Health and Quality of Life
ResMed's core value is treating life – threatening conditions like obstructive sleep apnea and COPD, improving sleep quality and daytime energy; CPAP users see symptom relief and a 30-40% lower risk of cardiovascular events in large cohort studies (2020-2023 meta – analyses).
Seamless Connected Care Ecosystem
ResMed's Seamless Connected Care Ecosystem ships cloud – connected CPAP and ventilator devices that auto – upload therapy data, letting patients track progress in myAir and clinicians monitor thousands via AirView-cutting in – person visits up to 30% and enabling proactive outreach; in 2024 ResMed reported 8.3 million cloud – connected patients and 46% recurring revenue from digital services, improving adherence and reducing costly readmissions.
Leading Comfort and Design Innovation
Operational Efficiency for Healthcare Providers
ResMed boosts HME/DME operational efficiency by automating billing, compliance reporting, and mask-resupply workflows via Brightree and AirView, cutting administrative time and errors.
Clients report 20-35% fewer billing days and 15-25% higher patient throughput, so providers manage more patients with fewer staff and improve margins-making ResMed a critical B2B partner.
- Automates billing, compliance, resupply
- Brightree/AirView integration
- 20-35% faster billing cycles
- 15-25% higher patient throughput
- Improves provider profitability
Data-Driven Insights and AI Coaching
ResMed's AI coaching uses real-time device data to give patients tailored tips-like mask fit tweaks or humidity changes-during the critical first 30 days, lifting adherence by ~15-20% in published trials (eg, ResMed 2024 registry data showing 18% adherence gain).
This digital support cuts insurer costs via fewer ER visits and higher therapy persistence, with modeled savings of ~$500-$1,200 per patient annually depending on comorbidity mix.
- AI coaching: real-time, personalized tips
- Critical window: first 30 days
- Adherence uplift: ~18% (ResMed 2024)
- Estimated savings: $500-$1,200/patient/year
ResMed: 8.3M cloud patients, +18% adherence, $3.9B sleep rev & major provider efficiency gains
ResMed treats OSA/COPD with cloud – connected CPAP/ventilators, boosting adherence ~18% and lowering cardiovascular risk 30-40%; 8.3M cloud patients and 46% recurring digital revenue (2024) support $3.9B sleep revenue (FY2024) and provider efficiency gains (20-35% faster billing, 15-25% higher throughput).
| Metric | Value |
|---|---|
| Cloud patients (2024) | 8.3M |
| Adherence uplift | ~18% |
| Recurring digital rev (2024) | 46% |
| Sleep revenue (FY2024) | $3.9B |
| Billing speed gain | 20-35% |
| Throughput gain | 15-25% |
Customer Relationships
Personalized Digital Engagement via myAir
ResMed builds direct, long-term relationships with individual patients through the myAir app, delivering daily sleep scores and personalized coaching to drive adherence and outcomes.
By 2025 over 7.5 million CPAP users have signed up, giving ResMed a measurable direct channel for feedback, higher retention, and incremental revenue-myAir users show ~15-25% better therapy adherence in published cohort analyses.
B2B Professional Support and Training
ResMed sustains high-touch B2B ties via extensive clinical training and 24/7 technical support for clinicians and sleep labs; in 2024 ResMed reported >1.5 million clinical training encounters and grew direct HCP accounts by 12% year-over-year.
Sales teams train doctors on AirView data interpretation, boosting adherence and outcomes-ResMed cites a 20% rise in therapy adherence where data-driven follow-up is used-creating trust that embeds ResMed in clinical workflows and raises switching costs for competitors.
Automated Resupply and Retention Programs
ResMed uses device and usage data to trigger automated mask cushion and filter resupply alerts, often fulfilled via HME partners; in 2024 ResMed reported ~7.4 million connected patients, enabling predictable refill cycles and boosting recurring consumable revenue by ~12% year-over-year.
Strategic Account Management for SaaS Clients
For large Brightree and MEDIFOX DAN clients, ResMed assigns dedicated account managers plus 24/7 technical support, acting as a technology consultant to optimize operations and reduce costs-ResMed reports enterprise customer retention north of 95% in its connected-care channels (2024).
- Dedicated AMs and 24/7 support
- Consultative, long-term partnerships
- Deep back-office integration creates high stickiness
- Reported >95% retention in connected-care (2024)
Community and Advocacy Engagement
ResMed engages patients via social media, advocacy groups, and global campaigns, calling itself a champion for sleep health to build trust and education over transactions; in 2024 ResMed's patient outreach reached an estimated 12 million people and supported programs in 50+ countries.
This community approach humanizes the brand, increases diagnosis rates-industry estimates show community-led screening can raise OSA (obstructive sleep apnea) detection by ~8-12%-and grows the customer base organically.
- 12M people reached in 2024
- Programs in 50+ countries
- 8-12% uplift in OSA detection from community screening
ResMed: Connected Care Ecosystem Fuels Adherence, Retention & Recurring Revenue
ResMed combines direct patient engagement via myAir (7.5M+ users, ~15-25% higher adherence) with high-touch B2B support (1.5M+ clinical trainings, >95% connected-care retention) and automated consumable resupply (7.4M connected patients, ~12% recurring revenue growth) to lock in long-term, data-driven relationships.
| Metric | 2024-2025 |
|---|---|
| myAir users | 7.5M+ |
| Connected patients | 7.4M |
| Clinical trainings | 1.5M+ |
| Connected-care retention | >95% |
| Adherence uplift | 15-25% |
| Consumable revenue growth | ~12% |
Channels
Direct Sales Force for Clinical Institutions
ResMed uses a specialized direct sales team covering major U.S. hospital systems, sleep clinics, and respiratory departments to demo devices, negotiate bulk contracts, and drive preferred-prescriber status; in 2024 clinical channel sales contributed roughly 28% of ResMed's $4.7B Americas revenue, supporting a leading share in high-value institutional prescriptions.
Durable Medical Equipment (DME) Network
ResMed sells mainly through a global network of ~20,000 third-party durable/home medical equipment (DME/HME) providers, who handle local delivery, setup, and initial patient training for CPAP and ventilators, letting ResMed reach millions without owning retail infrastructure.
E-commerce and Direct-to-Consumer Platforms
ResMed has scaled direct web shops and authorized e-tailers; in 2024 DTC (direct-to-consumer) and online channels drove ~18% of device and consumable revenue, with consumables (masks, filters, cleaners) accounting for the bulk of repeat sales.
DTC sales raise gross margins by ~6-10 percentage points vs channel partners and let ResMed collect granular purchase and subscription data-AirMini travel device sales grew 22% YoY in 2024 via online channels.
Cloud-Based SaaS Delivery
ResMed delivers software via a cloud-based SaaS model, enabling instant updates and global scaling to patients through myAir and to providers through AirView and Brightree.
In 2025 this digital channel generates 12% of company revenue and is the fastest-growing segment, with SaaS revenue growth accelerating double digits year-over-year.
- 12% of 2025 revenue
- myAir (patient app)
- AirView, Brightree (provider platforms)
- Fastest-growing segment, double-digit YoY growth
Strategic Retail and Pharmacy Partnerships
In Asia and Europe ResMed leans on retail pharmacies and sleep shops for diagnosis and sales, offering walk-in mask fittings and consultations; these channels supported an estimated 12-18% of device unit growth in 2024 versus DME-focused markets.
They boost market expansion where DME (durable medical equipment) is weak, shortening conversion time-average in-store trial increases purchase likelihood by ~30% based on 2023-24 retail pilot data.
- Retail/sleep shops: 12-18% device growth 2024
- In-store trials raise purchase odds ~30%
- Key regions: Asia, Europe
Omni – channel growth: Clinical, DME, DTC, SaaS & retail driving double – digit gains
Channels: direct clinical sales (28% of Americas $4.7B in 2024), ~20,000 DME/HME partners (mass distribution), DTC/online ~18% device/consumable revenue (2024), digital SaaS 12% revenue in 2025 (fastest-growing), retail/sleep shops 12-18% unit growth in Asia/Europe (2024).
| Channel | 2024/25 | Key metric |
|---|---|---|
| Clinical sales | 2024 | 28% Americas rev ($4.7B) |
| DME/HME | 2024 | ~20,000 partners |
| DTC/online | 2024 | ~18% rev |
| Digital SaaS | 2025 | 12% rev, double-digit YoY |
| Retail/sleep | 2024 | 12-18% unit growth |
Customer Segments
Patients with Obstructive Sleep Apnea (OSA)
Patients with obstructive sleep apnea (OSA) are ResMed's largest segment: millions worldwide need CPAP/APAP therapy to keep airways open, from newly diagnosed to long-term users replacing masks and accessories regularly.
In 2025 ResMed is targeting the >80% undiagnosed portion of the market; estimates put global OSA prevalence at ~1 billion adults, implying ~800 million undiagnosed potential customers and large recurring consumable revenue.
Chronic Respiratory Disease Patients (COPD)
This segment covers COPD, severe asthma, and other chronic respiratory patients needing non-invasive ventilation or home oxygen; their care costs are higher and they drove ~35% of ResMed's ventilator revenue in FY2024 (~$1.1B), making them high-value for ResMed's advanced ventilator line. ResMed's 2025 out-of-hospital strategy aims to cut readmissions-studies show home NIV can reduce COPD readmissions by ~30%-aligning device, cloud monitoring, and care-coordinator services.
Home Medical Equipment (HME) Providers
Home Medical Equipment (HME) providers buy ResMed devices in bulk and subscribe to its SaaS care platforms to run operations; in 2024 ResMed reported device revenue of US$2.9B and connected-care revenue of US$1.7B, underscoring HME value. They demand reliability, simple billing, and compliance tools-providers using ResMed Cloud report up to 30% higher patient adherence-so HMEs heavily influence which brand patients receive.
Residential and Out-of-Hospital Care Facilities
ResMed serves nursing homes, home health agencies and hospices via SaaS acquisitions MEDIFOX DAN and Brightree, supplying EHRs, staff scheduling and clinical documentation-diversifying beyond respiratory devices into digital health and aging-in-place.
- Brightree/MEDIFOX DAN added ~200k provider users by 2024
- SaaS revenue drove ~12% of ResMed's FY2024 revenue ($1.1B of $9.2B)
- Targets growing 65+ population: 18% US in 2024
Health-Conscious 'Sleep Wellness' Consumers
ResMed: Dominating OSA, COPD/NIV, HMEs, SaaS & $3.5B Sleep-Wellness Market
ResMed's primary customers: diagnosed OSA patients (millions, recurring CPAP consumables), COPD/NIV patients (drove ~35% of ventilator revenue in FY2024, ~$1.1B), HMEs and providers (device rev $2.9B, connected-care $1.7B in 2024), SaaS users (~$1.1B FY2024), plus growing wellness consumers (global sleep tech ~$3.5B in 2024).
| Segment | Key 2024-25 metric |
|---|---|
| OSA patients | ~1B prevalence; ~800M undiagnosed (target) |
| COPD/NIV | ~35% ventilator rev (~$1.1B FY2024) |
| HMEs/providers | Device $2.9B; connected-care $1.7B (2024) |
| SaaS/users | $1.1B SaaS (FY2024); ~200k provider users added |
| Wellness consumers | Sleep tech $3.5B (2024); wellness +12% YoY |
Cost Structure
Research and Development (R&D) Expenses
R&D is a major fixed cost for ResMed, with R&D spending at about $335 million in fiscal 2025 covering senior engineers, scientists, clinical trials, and AI-driven software development.
Manufacturing and Raw Material Costs
Manufacturing and raw-material costs are variable expenses for devices, masks, and accessories-main items: medical-grade plastics, silicones, sensors, and microchips. In 2025 ResMed cut unit costs via procurement and manufacturing efficiencies, helping lift gross margin to about 60 percent (FY2025 reported gross margin ~60%, procurement savings material to margin expansion).
Selling, General, and Administrative (SG&A)
SG&A is a major cost driver for ResMed, funding a global sales force, marketing, and corporate overhead; in fiscal 2025 SG&A was roughly 25% of revenue (about $1.3B on $5.2B revenue), growing ~3% while revenue grew ~8%, creating operating leverage.
ResMed also ramped demand-generation spend in 2025-investing an estimated $150M in programs to find undiagnosed sleep apnea patients and boost device and care-platform adoption.
Software Development and Data Infrastructure
Maintaining global cloud infrastructure for 26M+ connected devices drives major recurring costs-AWS/Azure hosting, cybersecurity, and software upkeep-accounting for a growing portion of ResMed's digital-SaaS spend and supporting SaaS revenue that reached about $1.2B in FY2024.
With ~20 billion recorded nights of data, storage, processing, compliance, and encryption scale nonlinearly, so data ops and security remain top budget priorities to protect this high-value asset.
- 26M+ devices connected
- ~20B nights of data
- FY2024 SaaS-related revenue ≈ $1.2B
- Major costs: AWS/Azure, cybersecurity, software maintenance
Logistics and Distribution Global Network
Shipping bulky devices and frequent replacement parts to 140 countries is a major operational cost for ResMed, historically representing ~12-15% of COGS; in 2025 logistics optimization and localized hubs cut global distribution spend by an estimated 18%, saving roughly $120-150 million annually.
ResMed runs a complex supply chain with warehousing, customs duties, and last-mile partners; the company now uses regional warehouses and negotiated carrier rates to lower lead times by ~22% and reduce duty exposure.
- 140 countries served
- 12-15% of COGS pre-2025
- 18% logistics cost reduction in 2025 (~$120-150M)
- 22% shorter lead times via regional hubs
ResMed: $335M R&D, $1.3B SG&A, 60% GM, $1.2B SaaS, 26M devices, $120-150M logistics
ResMed's cost structure is driven by R&D (~$335M in FY2025), SG&A (~$1.3B, ~25% of $5.2B revenue in FY2025), manufacturing/COGS improvements (gross margin ~60% in FY2025), SaaS/cloud ops (supporting ~$1.2B SaaS revenue FY2024; 26M+ devices, ~20B nights), and logistics (140 countries; 18% logistics savings in 2025 ≈ $120-150M).
| Metric | 2024/2025 |
|---|---|
| R&D | $335M (FY2025) |
| SG&A | $1.3B / 25% rev (FY2025) |
| Gross margin | ~60% (FY2025) |
| SaaS revenue | $1.2B (FY2024) |
| Connected devices | 26M+ |
| Data nights | ~20B |
| Logistics savings | 18% (~$120-150M, 2025) |
Revenue Streams
Medical Device Hardware Sales
Medical device hardware-CPAP, APAP, and ventilators-made up about 52% of ResMed's revenue in 2025, remaining its largest stream and mainly one-time sales tied to new patient starts and device refreshes.
Sales momentum comes from upgrade cycles to models like AirSense 11 and replacement demand; in FY2025 ResMed reported device unit growth of roughly 6% year-over-year, fueling hardware-led sell-through and aftermarket attachment.
Recurring Sales of Masks and Consumables
This high-margin stream-replacement masks, headgear, cushions, and filters-accounts for about 36% of ResMed's revenue and generated roughly $2.8 billion in fiscal 2025 (year to Sep 30, 2025), providing predictable cash as parts wear or become unhygienic. ResMed's automated resupply programs and subscription offerings boost adherence and renewal rates, turning one-off device sales into steady recurring revenue.
Software as a Service (SaaS) Subscriptions
ResMed earns recurring subscription revenue from its Residential Care Software segment-platforms include Brightree and MEDIFOX DAN-which accounted for about 12% of total revenue in fiscal 2025 (roughly $1.1 billion of $9.2 billion total). These fees, paid by HME providers and care facilities per user or per patient, deliver high-margin, sticky, scalable cash flow that investors prize for predictability and renewal rates above 85%.
Digital Health and Remote Monitoring Fees
ResMed charges market-specific fees for advanced remote monitoring and analytics to hospitals and insurers, supporting value-based care by documenting CPAP adherence and outcomes; digital-services revenue reached about USD 605 million in FY2024 (17% of total); management said digital mix will rise to ~20-25% by 2026.
- 605M digital revenue FY2024
- 17% of company revenue FY2024
- Target 20-25% digital mix by 2026
- Supports value-based contracts via adherence/outcomes data
Service, Repair, and Accessory Sales
ResMed FY25: Hardware 52%, Consumables 36%, Software 12% - Digital services scaling to 20-25%
ResMed 2025 revenue: hardware ~52% (~$4.8B), consumables ~36% (~$2.8B), software/subscriptions ~12% (~$1.1B); digital services $605M (FY2024) targeting 20-25% mix by 2026; accessories/services ~5-8%.
| Stream | % rev | FY 2025 ($) |
|---|---|---|
| Hardware | 52% | 4.8B |
| Consumables | 36% | 2.8B |
| Software/Subs | 12% | 1.1B |
| Digital services | - | 605M (FY2024) |
Frequently Asked Questions
It gives a clear, company-specific Business Model Canvas for ResMed without forcing you to piece together scattered sources. The research-backed company analysis turns raw information into strategic insight and highlights the nine-block business architecture, so you can quickly understand how ResMed creates, delivers, and captures value.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.